Feedback / Questions
CID-103 - CASI, Precision Autoimmune Therap
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-receives-fda-clearance-on-the-investigational-new-drug-ind-application-for-cid-103-in-immune-thrombocytopenia-itp-302145848.html
May 15, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next